Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-683 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-683 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate |
2016-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb54d293e7cfce2b36aa8b6e2d4fd2c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d739b40dacc51017474f6b2a9ee0b549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5eafe0a4bdf416d804acc95ddd897bf |
publicationDate |
2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2016329670-B2 |
titleOfInvention |
Leukocyte infiltration promoting agent and antitumor immunostimulatory agent |
abstract |
A substance that activates the lysophospholipid receptors is capable of normalizing abnormal blood vessels inside a tumor without affecting normal blood vessels, thereby causing or promoting the infiltration of leukocytes into some or all of the tumor region, and therefore is useful as a leukocyte infiltration promoter and a tumor immunoactivator. Furthermore, a substance that activates the lysophospholipid receptors can be used in combination with cancer immunotherapy to potentiate cancer immunotherapy, and therefore is useful as a cancer immunotherapy potentiator. |
priorityDate |
2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |